GlaxoSmithKline provides further update on divestment of non-core over-the-counter (OTC) brands Full Text
GlaxoSmithKline, 03/16/2012
GSK announced its intention to divest non–core Consumer Healthcare OTC products predominantly in the United States and Europe with aggregate sales of approximately £500 million. The proposed divestment is designed to realise value for shareholders and simplify GSK's Consumer Healthcare business by enabling it to focus on priority brands and markets.



